Blog

5 papers to read suggested by Vivek Subbiah

Photo from Vivek Subbiah/X

Jul 16, 2024, 13:55

5 papers to read suggested by Vivek Subbiah

We are presenting articles suggested by Vivek Subbiah:

1.’Pancreatic Cancer Surveillance and Survival of High-Risk Individuals’ published in JAMA Oncology/Source/

Authors: Amanda L. Blackford, Marcia Irene Canto, Mohamad Dbouk, Ralph H. Hruban, Bryson W. Katona, Amitabh Chak, Randall E. Brand, Sapna Syngal, James Farrell, Fay Kastrinos, Elena M. Stoffel, Anil Rustgi, Alison P. Klein, Ihab Kamel, Elliot Fishman, Jin He, Richard Burkhart, Eun Ji Shin, Anne Marie Lennon, Michael Goggins.

2.Comprehensive Discussions on KIT ATP-Binding Pocket/Activation Loop Mutations in Ripretinib Resistance published in Journal of Clinical Oncology/Source/

Authors: Yanzhe Xia and Xinhua Zhang

3. A study published ⁦in Nature outlines a clear pathway for how the Lupus disease likely develops, pointing to abnormalities in the immune systems of people with lupus. Interferon subverts an AHR–JUN axis to promote CXCL13+ T cells in lupus/Source/ ‘Interferon subverts an AHR–JUN axis to promote CXCL13⁺ T cells in lupus‘

Authors: Calvin Law, Vanessa Sue Wacleche, Ye Cao, Arundhati Pillai, John Sowerby, Brandon Hancock, Alice Horisberger, Sabrina Bracero, Viktoriya Skidanova, Zhihan Li, Ifeoluwakiisi Adejoorin, Eilish Dillon, Isaac J. Benque, Diana Pena Nunez, Daimon P. Simmons, Joshua Keegan, Lin Chen, Tina Baker, Phillip Z. Brohawn, Hussein Al-Mossawi, Ling-Yang Hao, Brian Jones, Navin Rao, Yujie Qu, Stephen E. Alves, Accelerating Medicines Partnership: RA/SLE Network, A. Helena Jonsson, Katharina S. Shaw, Ruth Ann Vleugels, Elena Massarotti, Karen H. Costenbader, Michael B. Brenner, James A. Lederer, Judd F. Hultquist, Jaehyuk Choi,Deepak A. Rao

5 papers to read suggested by Vivek Subbiah

4. ‘Saturation genome editing of BAP1 functionally classifies somatic and germline variants‘ published in Nature genetics./Source/

Authors: Andrew J. Waters, Timothy Brendler-Spaeth, Danielle Smith, Victoria Offord, Hong Kee Tan, Yajie Zhao, Sofia Obolenski, Maartje Nielsen, Remco van Doorn, Jo-Ellen Murphy, Prashant Gupta, Charlie F. Rowlands, Helen Hanson, Erwan Delage, Mark Thomas, Elizabeth J. Radford, Sebastian S. Gerety, Clare Turnbull, John R. B. Perry, Matthew E. Hurles, David J. Adams

Vivek Subbiah

5.’Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Lung Cancer‘

ctDNA-guided adaptive de-escalation TKI treatment strategy is feasible for patients with advanced NSCLC and undetectable ctDNA for achieving complete remission after local consolidative therapy./Source/

Authors: Song Dong, Zhen Wang, Jia Tao Zhang, Bingfa Yan, Chao Zhang, Xuan Gao, Hao Sun, Yang-Si Li, Hong Hong Yan, Hai-Yan Tu, Si-Yang Maggie Liu, Yuhua Gong, Wei Gao, Jie Huang, Ri-Qiang Liao, Jun-Tao Lin, E E. Ke, Zelong Xu, Xue Zhang, Xuefeng Xia, An-Na Li, Si-Yang Liu, Yi Pan, Jin-Ji Yang, Wen Zhao Zhong, Xin Yi, Qing Zhou, Xue-Ning Yang, Yi-Long Wu.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA).

He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.

A. Helena Jonsson Alice Horisberger Alison P. Klein Amanda L. Blackford Amitabh Chak An-Na Li Andrew J. Waters Anil Rustgi Anne Marie Lennon Arundhati Pillai Bingfa Yan Brandon Hancock Brian Jones Bryson W. Katona Calvin Law cancer Chao Zhang Charlie F. Rowlands Clare Turnbull Daimon P. Simmons Danielle Smith David J. Adams Deepak A. Rao Diana Pena Nunez E-E Ke Eilish Dillon Elena M. Stoffel Elena Massarotti Elizabeth J. Radford Elliot Fishman Erwan Delage Eun Ji Shin Fay Kastrinos Hai-Yan Tu Hao Sun Helen Hanson Hong Kee Tan Hong-Hong Yan Hussein Al-Mossawi Ifeoluwakiisi Adejoorin Ihab Kamel Isaac J. Benque Jaehyuk Choi JAMA Oncology James A. Lederer James Farrell Jia Tao Zhang Jie Huang Jin He Jin-Ji Yang Jo-Ellen Murphy John R. B. Perry John Sowerby Joshua Keegan Journal of Clinical Oncology Judd F. Hultquist Jun-Tao Lin Karen H. Costenbader Katharina S. Shaw Lin Chen Ling-Yang Hao Maartje Nielsen Marcia Irene Canto Mark Thomas Matthew E. Hurles Michael B. Brenner Michael Goggins Mohamad Dbouk Navin Rao OncoDaily Oncology Pancreatic Cancer Phillip Z. Brohawn Prashant Gupta Qing Zhou Ralph H. Hruban Randall E. Brand Remco van Doorn Ri-Qiang Liao Richard Burkhart Ruth Ann Vleugels Sabrina Bracero Sapna Syngal Sebastian S. Gerety Si-Yang Liu Si-Yang Maggie Liu Sofia Obolenski Song Dong Stephen E. Alves Timothy Brendler-Spaeth Tina Baker Vanessa Sue Wacleche Victoria Offord Viktoriya Skidanova Vivek Subbiah Wei Gao Wen-Zhao Zhong Xin Yi Xinhua Zhang Xuan Gao Xue Zhang Xue-Ning Yang Xuefeng Xia Yajie Zhao Yang-Si Li Yanzhe Xia Ye Cao Yi Pan Yi-Long Wu Yuhua Gong Yujie Qu Zelong Xu Zhen Wang Zhihan Li

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage